AstraZeneca Pharmaceuticals Inc. filed a motion on Wednesday to block Dr. Christopher Reist from testifying for Handa Pharmaceuticals LLC, a rival pharmaceutical company, in an ongoing patent infringement case over AstraZeneca’s Seroquel XR®. Dr. Reist worked on the clinical trials for Seroquel XR® between 2001 and 2007 as one of it’s paid speakers. Handa has selected Dr. Reist as an expert witness in the infringement case, something AstraZeneca states will create a conflict of interest. AstraZeneca is represented by Finnegan.
Award/Ranking
Managing IP Americas Awards 2024: Finnegan Shortlisted for Nine Awards, Including Firm of the Year
March 12, 2024
Commentary
February 29, 2024
Press Release
Finnegan Secures Another Patent Victory for BMW Group in the District of Delaware
February 27, 2024
Award/Ranking
Managing IP EMEA Awards 2024: Finnegan Shortlisted for Global Firm of the Year Award
February 19, 2024
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.